Roche: Standing still for 7 more years – Raising awareness of the forgotten patients

Roche, a pharmaceutical company, increased awareness of primary progressive multiple sclerosis in Russia by launching an educational website that featured an informative video.

Contrary to common myths, multiple sclerosis is a disease of young people, who are still building their careers and families. One more hard truth is that 10% of them, suffering from a less common primary progressive type of the disease (PPMS), may en

became a trustworthy source of up-to-date information about PPMS with 13,000 visitors monthly, while communities in VKontakte and Facebook attracted 6,000+ followers over the course of the campaign, which represents about a third of the total number of patients in Russia. The engagement rate is 8 times higher than the average in VKontakte. Most importantly, on 7th November 2019, ocrelizumab was recommended for inclusion in the 12 Expensive Drugs Program by the Russian Health Ministry's commission, which means that for the first time the PPMS patients will get government budgeted access to specialized innovative treatment starting from 2021 and will be able to spend more time with their beloved ones once the document is finally signed.

WARC subscribers can sign in to keep reading

Not a subscriber?

WARC helps you to plan, create and deliver more effective marketing

  • Prove your case and back-up your idea

  • Get expert guidance on strategic challenges

  • Tackle current and emerging marketing themes

WARC consistently delivers valuable insights that help to make me look like an expert in front of my colleagues and clients.

Dasha Boryso
Strategy Partner, Fetch

You’re in good company

We work with 80% of Forbes' most valuable brands* and 80% of the world's top top-of-the-class agencies.

* Top 10 brands